Milciclib is under clinical development by Tiziana Life Sciences and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Milciclib’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Milciclib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Milciclib overview

Milciclib (PHA-848125) is under development for the treatment of thymoma, metastatic hepatic cellular carcinoma (HCC), thyroid cancer, prostate cancer, solid tumors including non small cell lung cancer, pancreatic and colon cancer and thymic carcinoma. It is administered orally in the form of the capsule. It is developed based on kinase platform technology. The drug candidate acts by targeting cyclin-dependent kinase-1 (CDK-1), cyclin-dependent kinase-2 (CDK-2), cyclin-dependent kinase-4 (CDK-4), cyclin-dependent kinase-5 (CDK-5), cyclin-dependent kinase-7 (CDK-7), pan src family kinases  and tropomyosin receptor kinase A (TRKA). The drug candidate was also under development for recurrent malignant glioma and malignant pleural mesothelioma.

Tiziana Life Sciences overview

Tiziana Life Sciences Ltd (Tiziana), formerly Tiziana Life Sciences, is a clinical-stage biotechnology company that discovers and develops drugs to treat inflammatory diseases and cancers. Its lead product candidate, Milciclib (TZLS-201), intended for the treatment of thymic carcinoma. The company’s other clinical programs includes Foralumab (TZLS-401), a human engineered anti-human CD3 antibody intended for the treatment of Crohn’s disease and Nonalcoholic steatohepatitis. The company’s preclinical stage candidates include anti-IL6R (TZLS-501), a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor. Tiziana is headquartered in Hamilton, Bermuda, the UK.

Quick View Milciclib LOA Data

Report Segments
  • Innovator
Drug Name
  • Milciclib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.